PATIENT INFORMATION LEAFLET
ESBERIVEN 100 mg/ml oral solution
Troxerutina
Read this leaflet carefully before you start taking this medicine, because it contains important information for you
Esberivenbelongs to the group of capillary-protecting medications.
It is indicated for short-term use (for two to three months) of edema and related symptoms with chronic venous insufficiency, such as: heavy, painful, and swollen legs.
Do not take Esberiven
Warnings and precautions
Be especially careful with Esberiven.
Consult your doctor or pharmacist before starting to take Esberiven.
Use of Esberiven with other medications
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication, including those purchased without a prescription.
No interactions with other medications are known.
Use of Esberiven with food
No interactions with food are known.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or intend to become pregnant, consult your doctor or pharmacist before using this medication.
Pregnancy
No appropriate experience is available regarding the safety of Esberiven during pregnancy. Its use in pregnant women will always be weighed against the relationship between the benefits provided and the possible risk of its administration.
Breastfeeding
Troxerutina does not pass into breast milk in significant amounts. No adverse effects have been described for the breastfeeding infant.
Driving and operating machinery
No effect on the ability to drive and operate machinery.
Esberiven 100 mg/ml oral solution contains methyl parahydroxybenzoate (E-218) and propyl parahydroxybenzoate (E-216)
It may cause allergic reactions (possibly delayed) and, exceptionally, bronchospasm (sudden sensation of choking) because it contains methyl parahydroxybenzoate (E-218) and propyl parahydroxybenzoate (E-216).
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.
This medication is administered orally.
Adults:
The recommended dose is 10 milliliters per day, in one 10 ml dose or in two 5 ml doses.
This medication can be taken mixed with a little cold milk with or without sugar, fruit juice, or sugar-sweetened soda water.
If you take more Esberiven than you should
Nausea or vomiting and stomach pain may occur. In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
If you forgot to take Esberiven
Do not take a double dose to compensate for the missed doses.
If you interrupt treatment with Esberiven
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, Esberiven can produce adverse effects, although not all people will experience them.
The adverse effects of Esberiven are generally infrequent, mild, and transient.
The adverse reactions that have been observed are:
Gastrointestinal Disorders:abdominal discomfort, dyspepsia (heavy digestion, burning, and acidity), nausea.
Dermatological and Subcutaneous Tissue Disorders:cutaneous eruption.
Nervous System Disorders:headache.
If you experience adverse effects, consult your doctor or pharmacist, even if they do not appear in this prospectus.
Keep out of sight and reach of children.
No special storage conditions are required.
Do not use this medication after the expiration date that appears on the box after CAD. The expiration date is the last day of the month indicated.
Medicines should not be disposed of through drains or in the trash.Deposit the packaging and unused medicines at the SIGRE collection pointof the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and unused medicines.This will help protect the environment.
Composition of Esberiven100 mg/ml oral solution
Appearance of the product and content of the container
Esberiven is an oral solution, transparent and of intense yellow color thatis presented in a glass vialtopaz,with a polypropylene/polycarbonate high-density (PP/HDPE) cap with a child-resistant closure, that contains200 ml of solution accompanied by a dosing cup.
Holder of the marketing authorization
Faes Farma, S.A.
48940 Leioa(Bizkaia)
Spain
Responsible for manufacturing
Faes Farma, S.A.
Parque Científico y Tecnológico de Bizkaia
Ibaizabal Bidea, Edificio 901
48160 Derio (Bizkaia)
Spain
Last review date of this leaflet:December 2004
The detailed and updated information of this medicine is available on the website of the Spanish Agency of Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es /
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.